In the pursuit to cure* chronic hepatitis C virus (HCV) genotype 1 infection…Consider once-daily OLYSIO® in combination with sofosbuvir (SOF) for your individual patient needs
Determine the appropriate OLYSIO® treatment duration for your patients
For treatment-naïve and treatment-experienced† patients with and without compensated (Child-Pugh A) cirrhosis
- Test all patients for evidence of current or prior hepatitis B virus infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with OLYSIO®.
- Monitor liver chemistry tests before and during OLYSIO® combination therapy
- OLYSIO® should be taken with food
No treatment-stopping rules apply to the combination of OLYSIO® with SOF.
Patients with HCV G1a and Q80K polymorphism
In HCV genotype 1a‑infected patients with compensated cirrhosis, screening for the presence of virus with the NS3 Q80K polymorphism may be considered prior to initiation of treatment with OLYSIO® with sofosbuvir.
*Virologic cure (SVR12) was defined as sustained virologic response 12 weeks after actual (OPTIMIST-1) or planned (COSMOS) end of treatment (EOT).
†Treatment-experienced patients include prior relapsers, prior partial responders, and prior null responders who failed prior IFN-based therapy.